Phase I/II, randomized, MultiCenter, dose-ascension study of the p38MAPK inhibitor scio469 in patients with myelodysplastic syndrome (MDS). 48th Annual Meeting of the American-Society-of-Hematology Sokol, L., Cripe, L., Kantarjian, H., Sekeres, M. A., Parmar, S., Greenberg, P., Goldberg, S., Bhushan, V., Shammo, J., Hohl, R., Li, Y., Lowe, A., Zhu, J., List, A. AMER SOC HEMATOLOGY. 2006: 751A–751A

View details for Web of Science ID 000242440003447